8
Oct
2024

Medichem S.A.

Exhibitor at CPHI Milan 2024 stand 10F42, Finished Dosage Formulations
About Us

Medichem is a vertically integrated pharmaceutical company that is specialized in the development and manufacture of APIs and FDFs for the global generics industry.  
Our portfolio offers about 45 APIs and 20 FDFs, including highly potent products, as well as a wide range of services, ranging from R&D development to contract manufacturing and licensing. It is also a world leader in Chlorhexidine products. 
The group boasts of 50 years of experience in the sector, and guarantees the highest standards of quality, operational e...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • ES
  • 2015
    On CPHI since
  • 250 - 499
    Employees
Company types
Manufacturer/Innovator
View company profile
Contact info
  • +34 93 477 6440
  • Website
  • Fructuós Gelabert, 6-8, Conata II Building, 5th floor, 08970, Sant Joan Despi, Barcelona, Spain
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 10F42, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • SUGAMMADEX SODIUM FDF

    Product SUGAMMADEX SODIUM FDF

    SOLUTION FOR INJECTION ANESTHESIA FDF
  • PRUCALOPRIDE succinate FDF

    Product PRUCALOPRIDE succinate FDF

    film-coated tablets - chronic constipation FDF
  • DAPTOMYCIN FDF

    Product DAPTOMYCIN FDF

    Medichem S.A. offers wide range of finished dosage forms for licencing which includes Daptomycin. Indication: Antibiotic. Pharmaceutical form: Powder for solution for injection or infusion in glass vial. Strength: 350 mg, 500 mg. Dossier status: EU filed.
  • RIVAROXABAN FDF

    Product RIVAROXABAN FDF

    Medichem S.A. offers wide range of pharmaceutical APIs and FDF which includes Rivaroxaban. Indication: Antithrombotic. Contact us for more information.
  • SUNITINIB MALATE FDF

    Product SUNITINIB MALATE FDF

    Medichem S.A. offers a wide range of finished dosage forms for licencing which includes Sunitinib Malate. Indication: Kidney Cancer/ GIT Stromal Tumors. Pharmaceutical form: Capsules. Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg. Dossier status: EU filed.